Compounds > 3-(2-aminoethyl)-5-(4-ethoxybenzylidene)thiazolidine-2-4-dione

3-(2-aminoethyl)-5-(4-ethoxybenzylidene)thiazolidine-2-4-dione and Melanoma

3-(2-aminoethyl)-5-(4-ethoxybenzylidene)thiazolidine-2-4-dione has been researched along with Melanoma* in 1 studies

Other Studies

1 other study(ies) available for 3-(2-aminoethyl)-5-(4-ethoxybenzylidene)thiazolidine-2-4-dione and Melanoma

ArticleYear
Structural modifications of (Z)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)thiazolidine-2,4-dione that improve selectivity for inhibiting the proliferation of melanoma cells containing active ERK signaling.
    Organic & biomolecular chemistry, 2013, Jun-14, Volume: 11, Issue:22

    We herein report on the pharmacophore determination of the ERK docking domain inhibitor (Z)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)thiazolidine-2,4-dione, which has led to the discovery of compounds with greater selectivities for inhibiting the proliferation of melanoma cells containing active ERK signaling.

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; HeLa Cells; Humans; MAP Kinase Signaling System; Melanoma; Structure-Activity Relationship; Thiazolidinediones

2013